Applied BioCode Corporation (TPE:6598)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
24.40
+0.80 (3.39%)
Mar 10, 2026, 9:36 AM CST
8.20%
Market Cap 2.43B
Revenue (ttm) 443.69M
Net Income (ttm) -207.78M
Shares Out 102.81M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 39,043
Average Volume 380,860
Open 23.40
Previous Close 23.60
Day's Range 23.40 - 24.50
52-Week Range 17.00 - 26.00
Beta 0.79
RSI 45.59
Earnings Date Mar 13, 2026

About Applied BioCode

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic ... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2016
Country Cayman Islands
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6598
Full Company Profile

Financial Performance

In 2024, Applied BioCode's revenue was 343.07 million, a decrease of -13.18% compared to the previous year's 395.17 million. Losses were -260.81 million, 58.8% more than in 2023.

Financial Statements

News

There is no news available yet.